OraSure Technologies (NASDAQ:OSUR) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday.
Several other research firms have also recently weighed in on OSUR. Canaccord Genuity restated a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, ValuEngine upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.25.
Shares of OraSure Technologies (OSUR) opened at $18.46 on Thursday. The firm has a market cap of $1,130.00, a price-to-earnings ratio of 28.84, a PEG ratio of 5.17 and a beta of 1.60. OraSure Technologies has a 52-week low of $10.75 and a 52-week high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. The firm had revenue of $52.00 million for the quarter, compared to analysts’ expectations of $50.20 million. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The business’s quarterly revenue was up 46.5% on a year-over-year basis. During the same quarter last year, the company posted $0.13 EPS. analysts forecast that OraSure Technologies will post 0.29 earnings per share for the current year.
In related news, EVP Brian Smith sold 20,000 shares of OraSure Technologies stock in a transaction on Friday, February 16th. The shares were sold at an average price of $17.97, for a total value of $359,400.00. Following the transaction, the executive vice president now owns 28,075 shares in the company, valued at approximately $504,507.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Stephen S. Phd Tang sold 23,333 shares of OraSure Technologies stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total transaction of $419,294.01. Following the completion of the transaction, the director now owns 59,749 shares in the company, valued at approximately $1,073,689.53. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the stock. Elkfork Partners LLC purchased a new position in OraSure Technologies in the 4th quarter worth $143,000. Oppenheimer Asset Management Inc. purchased a new position in OraSure Technologies in the 3rd quarter worth $186,000. Shikiar Asset Management Inc. purchased a new position in OraSure Technologies in the 4th quarter worth $207,000. Belpointe Asset Management LLC purchased a new position in OraSure Technologies in the 3rd quarter worth $315,000. Finally, Sei Investments Co. raised its position in OraSure Technologies by 422.4% in the 3rd quarter. Sei Investments Co. now owns 14,925 shares of the medical instruments supplier’s stock worth $336,000 after purchasing an additional 12,068 shares during the period. Institutional investors own 93.67% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.